Key Takeaways
- Pete Pharma partners with Atrium24 to provide 3D printing solutions for independent pharmacies
- The partnership offers preferred pricing on Pete Pharma's 3D printing platform, powered by FABRx technology
- The goal is to expand access to automated solid dosage form manufacturing and enable pharmacies to scale differentiated offerings
Introduction to the Partnership
Pete Pharma has announced a strategic partnership with Atrium24 Technologies, Inc., a leading pharmacy technology and GPO platform serving independent pharmacies nationwide. This partnership establishes Pete Pharma as the primary pharmaceutical 3D printing provider within the Atrium24 GPO.
Benefits of the Partnership
Through this collaboration, Atrium24 member pharmacies will gain access to preferred pricing on the Pete Pharma 3D printing platform, powered by FABRx technology. The platform enables the production of a wide range of dosage forms, including:
- Immediate-release tablets
- Extended-release formulations
- Oral films
- Troches
- Chewables
- Suppositories
Partnership Details
The partnership aims to create a more connected and scalable pathway for independent pharmacies to adopt advanced dosage form manufacturing. Atrium24's Dotti platform will feature a dedicated Pete Pharma partner presence, enabling:
- Streamlined onboarding
- Coordinated marketing initiatives
- Structured sales enablement across Atrium24's member network
Comparison of 3D Printing Platforms
| Platform | Technology | Dosage Forms |
|---|---|---|
| Pete Pharma | FABRx | Immediate-release tablets, extended-release formulations, oral films, troches, chewables, suppositories |
| Other Platforms | Various | Limited dosage forms |
Advantages of the Partnership
The partnership between Pete Pharma and Atrium24 offers several advantages, including:
- Expanded access to automated solid dosage form manufacturing
- Enablement of independent pharmacies to scale differentiated offerings
- Creation of a more connected and scalable pathway for advanced dosage form manufacturing
Bottom Line
In summary, the partnership between Pete Pharma and Atrium24 is a significant development in the pharmaceutical 3D printing industry. By providing preferred pricing on Pete Pharma's 3D printing platform, the partnership aims to expand access to automated solid dosage form manufacturing and enable independent pharmacies to scale differentiated offerings. With the potential to create a more connected and scalable pathway for advanced dosage form manufacturing, this partnership is likely to have a profound impact on the industry.